Leveraging innovation loans for biotechs: building resilient funding pathways
In this blog, Alastair Hall, Hub Eurasia Director, FI Group, explores how Innovate UK Innovation Loans are helping biotech SMEs bridge the gap between research and commercialisation. He highlights why they are most effective when combined with other funding sources to build a resilient strategy for growth.
The UK biotech sector stands at a crossroads. Scientific innovation is thriving, yet the funding environment has become more complex. Since 2021, real-terms public R&D investment has declined, eroding the purchasing power of government support. Biotech firms report that competition for grants is fiercer than ever, while venture capital investors remain cautious amid wider economic uncertainty.
Against this backdrop, Innovate UK Innovation Loans are gaining traction. By providing flexible finance tailored to the needs of high-growth R&D companies, they offer an alternative to dilutive equity or inaccessible bank lending. Yet their greatest value lies in being combined with other channels, from R&D tax relief and Innovate UK grants to European programmes such as Horizon Europe and the EIC Accelerator.
What are Innovate UK Innovation Loans?
Innovation Loans provide non-dilutive finance specifically for late-stage R&D and early commercialisation. SMEs can now access:
- Loans between £100,000 and £5 million (recently raised from £2 million).
- Funding for up to 100% of eligible project costs.
- Project durations up to 5 years, with a maximum loan lifecycle of 7 years.
- Low initial interest of 3.7%, rising to 7.4% during repayment.
Eligible activities include R&D, prototyping, tooling, marketing, customer testing, capital deployment, pre-commercial readiness, trials, and scale-up operations.
Download the Guide to Innovation Loans Success.
This makes them particularly relevant for biotech SMEs needing to finance:
- Phase I and II clinical trials.
- Scaling biomanufacturing processes.
- Regulatory preparation for MHRA and EMA approvals.
By preserving equity ownership and offering patient repayment schedules, Innovation Loans give biotech founders breathing room to reach the next milestone without sacrificing long-term value.
The UK R&D funding squeeze
Despite ambitions to position the UK as a science superpower, real-terms government R&D spending has contracted since 2021. SMEs face tougher grant competition, and many report difficulty securing sufficient finance to move from research to market.
The BIA TechBio 2024 report underlines this issue, noting that while UK firms lead in AI-driven drug discovery, genomics, and digital clinical trials, scaling is often held back by financial constraints. This makes patient finance such as Innovation Loans, paired with other funding channels, essential for maintaining momentum.
Building a blended funding model
A resilient biotech funding strategy integrates multiple sources:
- R&D Tax Relief, providing essential cash flow benefits.
- Innovate UK grants, such as the Biomedical Catalyst, which remain a cornerstone for early science.
- Horizon Europe, where FI Group’s analysis shows UK companies continue to achieve success rates around 18% in health-related calls.
- EIC Accelerator, offering up to €2.5 million in grants plus equity finance for breakthrough projects.
- Private investment, which becomes more accessible once public funds validate a company’s potential.
Dr Fawzi Abou-Chahine, Funding Director at FI Group UK, explains:
For biotech SMEs, the funding ecosystem is more fragmented than ever. Innovation Loans offer an important bridge, but their value multiplies when combined with R&D tax relief, Innovate UK grants, and European schemes such as the EIC Accelerator. The goal is to build a strategic roadmap that sustains projects from early clinical milestones right through to commercial launch.
Horizon Europe: an international dimension
FI Group’s Horizon Europe success rate analysis shows that UK firms continue to perform strongly despite Brexit-related complexities. Health-themed calls average an 18% success rate, proving that UK biotechs can still compete effectively.
For many SMEs, Innovation Loans act as a bridge, financing preparatory work and positioning companies for stronger Horizon Europe and EIC bids.
Contact the FI Group team to create a full funnel innovation funding strategy.
Action points for biotech leaders
- Audit eligibility – check if your project aligns with Innovation Loan requirements.
- Plan a blended roadmap – structure funding across grants, loans, and tax credits.
- Avoid double funding risks – ensure claims are compliant.
- Look beyond the UK – consider Horizon Europe and EIC programmes.
- Engage experts early – advisors such as FI Group can strengthen applications and optimise outcomes.
Conclusion
The UK biotech sector continues to innovate at pace, but the funding climate is constrained. With real-terms R&D investment falling and private capital harder to secure, SMEs must adopt resilient finance strategies. Innovation Loans are a powerful tool, especially when integrated with R&D tax relief, Innovate UK grants, and European programmes like the EIC Accelerator. FI Group’s work with companies such as Stablepharma demonstrates how these instruments can be combined to achieve growth and global impact.
As the UK strives to maintain its leadership in life sciences, ensuring SMEs have access to well-structured finance will be critical. With the right roadmap, finance need not be the barrier that prevents scientific breakthroughs from reaching patients.
Book a 25-minute introductory meeting with FI Group.
